Rabbit polyclonal primary
Muc1 Antibody (ER1902-10)
Synthetic peptide within human muc1 aa 100-1000.
MCF-7 cell lysates, MCF-7, human colon tissue, human skin tissue, human breast carcinoma tissue, human kidney tissue, human uterus tissue.
Store at +4C after thawing. Aliquot store at -20C. Avoid repeated freeze / thaw cycles.
1*PBS (pH7.4), 0.2% BSA, 50% Glycerol. Preservative: 0.05% Sodium Azide.
Peptide affinity purified
Predicted band size 122 kDa.
ADMCKD antibody; ADMCKD1 antibody; Breast carcinoma associated antigen DF3 antibody; Breast carcinoma-associated antigen DF3 antibody; CA 15-3 antibody; CA15 3 antibody; CA15 3 antigen antibody; CA15-3 antibody; CA15.3 antibody; Cancer antigen 15-3 antibody; Carcinoma associated mucin antibody; Carcinoma-associated mucin antibody; CD 227 antibody; CD227 antibody; DF3 antigen antibody; EMA antibody; Episialin antibody; Epithelial Membrane Antigen antibody; H23 antigen antibody; H23AG antibody; KL 6 antibody; KL-6 antibody; KL6 antibody; Krebs von den Lungen-6 antibody; MAM 6 antibody; MAM6 antibody; MCD antibody; MCKD antibody; MCKD1 antibody; Medullary cystic kidney disease 1 (autosomal dominant) antibody; Medullary cystic kidney disease, autosomal dominant antibody; MUC 1 antibody; MUC-1 antibody; MUC-1/SEC antibody; MUC-1/X antibody; MUC1 antibody; MUC1-alpha antibody; MUC1-beta antibody; MUC1-CT antibody; MUC1-NT antibody; MUC1/ZD antibody; MUC1_HUMAN antibody; Mucin 1 antibody; Mucin 1 cell surface associated antibody; Mucin 1 transmembrane antibody; Mucin 1, cell surface associated antibody; Mucin-1 subunit beta antibody; Peanut reactive urinary mucin antibody; Peanut-reactive urinary mucin antibody; PEM antibody; PEMT antibody; Polymorphic epithelial mucin antibody; PUM antibody; Tumor associated epithelial membrane antigen antibody; Tumor associated epithelial mucin antibody; Tumor associated mucin antibody; Tumor-associated epithelial membrane antigen antibody; Tumor-associated mucin antibody
Expressed on the apical surface of epithelial cells, especially of airway passages, breast and uterus. Also expressed in activated and unactivated T-cells. Overexpressed in epithelial tumors, such as breast or ovarian cancer and also in non-epithelial tumor cells. Isoform Y is expressed in tumor cells only.
During fetal development, expressed at low levels in the colonic epithelium from 13 weeks of gestation.
Highly glycosylated (N- and O-linked carbohydrates and sialic acid). O-glycosylated to a varying degree on serine and threonine residues within each tandem repeat, ranging from mono- to penta-glycosylation. The average density ranges from about 50% in human milk to over 90% in T47D breast cancer cells. Further sialylation occurs during recycling. Membrane-shed glycoproteins from kidney and breast cancer cells have preferentially sialyated core 1 structures, while secreted forms from the same tissues display mainly core 2 structures. The O-glycosylated content is overlapping in both these tissues with terminal fucose and galactose, 2- and 3-linked galactose, 3- and 3,6-linked GalNAc-ol and 4-linked GlcNAc predominating. Differentially O-glycosylated in breast carcinomas with 3,4-linked GlcNAc. N-glycosylation consists of high-mannose, acidic complex-type and hybrid glycans in the secreted form MUC1/SEC, and neutral complex-type in the transmembrane form, MUC1/TM.; Proteolytic cleavage in the SEA domain occurs in the endoplasmic reticulum by an autoproteolytic mechanism and requires the full-length SEA domain as well as requiring a Ser, Thr or Cys residue at the P + 1 site. Cleavage at this site also occurs on isoform MUC1/X but not on isoform MUC1/Y. Ectodomain shedding is mediated by ADAM17.; Dual palmitoylation on cysteine residues in the CQC motif is required for recycling from endosomes back to the plasma membrane.; Phosphorylated on tyrosines and serine residues in the C-terminal. Phosphorylation on tyrosines in the C-terminal increases the nuclear location of MUC1 and beta-catenin. Phosphorylation by PKC delta induces binding of MUC1 to beta-catenin/CTNNB1 and thus decreases the formation of the beta-catenin/E-cadherin complex. Src-mediated phosphorylation inhibits interaction with GSK3B. Src- and EGFR-mediated phosphorylation on Tyr-1229 increases binding to beta-catenin/CTNNB1. GSK3B-mediated phosphorylation on Ser-1227 decreases this interaction but restores the formation of the beta-cadherin/E-cadherin complex. On T-cell receptor activation, phosphorylated by LCK. PDGFR-mediated phosphorylation increases nuclear colocalization of MUC1CT and CTNNB1.; The N-terminal sequence has been shown to begin at position 24 or 28.
The alpha subunit has cell adhesive properties. Can act both as an adhesion and an anti-adhesion protein. May provide a protective layer on epithelial cells against bacterial and enzyme attack. The beta subunit contains a C-terminal domain which is involved in cell signaling, through phosphorylations and protein-protein interactions. Modulates signaling in ERK, SRC and NF-kappa-B pathways. In activated T-cells, influences directly or indirectly the Ras/MAPK pathway. Promotes tumor progression. Regulates TP53-mediated transcription and determines cell fate in the genotoxic stress response. Binds, together with KLF4, the PE21 promoter element of TP53 and represses TP53 activity.